Researchers at the UCLA (University of California, Los Angeles) have developed a new methodology to predict the reason behind the varied response of some patients battling advanced melanoma to the new breakthrough drug pembrolizumab (Keytruda). The study, led by UCLA Jonsson Comprehensive Cancer Center members Drs. Paul Tumeh and Antoni Ribas, primary investigator of pembrolizumab, is the first of its kind since the FDA approved the use of Keytruda in September ...Thursday 27 November 2014
Researchers Discover Reason Behind Patient's Mixed Response to a Melanoma Breakthrough Drug
Researchers at the UCLA (University of California, Los Angeles) have developed a new methodology to predict the reason behind the varied response of some patients battling advanced melanoma to the new breakthrough drug pembrolizumab (Keytruda). The study, led by UCLA Jonsson Comprehensive Cancer Center members Drs. Paul Tumeh and Antoni Ribas, primary investigator of pembrolizumab, is the first of its kind since the FDA approved the use of Keytruda in September ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment